FGFR1‐amplified lung cancer models respond to FGFR inhibitors in preclinical studies in both non‐small cell lung cancer (NSCLC) and small‐cell lung cancer (SCLC), especially in SqCLC, with 9.3% in stage I, 22% in stage II, and 19% in stage IV with brain metastasis.36 This evidence concerns the gene FGFR1 and non-small cell lung carcinoma.